<?xml version='1.0' encoding='utf-8'?>
<document id="18056254"><sentence text="CYP2D6-Mediated metabolism of a novel acyl coenzyme A:cholesterol acyltransferase inhibitor, pactimibe, and its unique plasma metabolite, R-125528."><entity charOffset="54-65" id="DDI-PubMed.18056254.s1.e0" text="cholesterol" /></sentence><sentence text="Pactimibe sulfate is a novel acyl coenzyme A:cholesterol acyltransferase inhibitor"><entity charOffset="0-17" id="DDI-PubMed.18056254.s2.e0" text="Pactimibe sulfate" /><entity charOffset="29-33" id="DDI-PubMed.18056254.s2.e1" text="acyl" /><entity charOffset="45-56" id="DDI-PubMed.18056254.s2.e2" text="cholesterol" /><entity charOffset="57-67" id="DDI-PubMed.18056254.s2.e3" text="acyl" /><pair ddi="false" e1="DDI-PubMed.18056254.s2.e0" e2="DDI-PubMed.18056254.s2.e0" /><pair ddi="false" e1="DDI-PubMed.18056254.s2.e0" e2="DDI-PubMed.18056254.s2.e1" /><pair ddi="false" e1="DDI-PubMed.18056254.s2.e0" e2="DDI-PubMed.18056254.s2.e2" /><pair ddi="false" e1="DDI-PubMed.18056254.s2.e0" e2="DDI-PubMed.18056254.s2.e3" /><pair ddi="false" e1="DDI-PubMed.18056254.s2.e1" e2="DDI-PubMed.18056254.s2.e1" /><pair ddi="false" e1="DDI-PubMed.18056254.s2.e1" e2="DDI-PubMed.18056254.s2.e2" /><pair ddi="false" e1="DDI-PubMed.18056254.s2.e1" e2="DDI-PubMed.18056254.s2.e3" /><pair ddi="false" e1="DDI-PubMed.18056254.s2.e2" e2="DDI-PubMed.18056254.s2.e2" /><pair ddi="false" e1="DDI-PubMed.18056254.s2.e2" e2="DDI-PubMed.18056254.s2.e3" /></sentence><sentence text=" We conducted metabolic studies of pactimibe and its plasma metabolite, R-125528" /><sentence text=" Pactimibe had multiple metabolic pathways including indolin oxidation to form R-125528, omega-1 oxidation, N-dealkylation, and glucuronidation"><entity charOffset="53-60" id="DDI-PubMed.18056254.s4.e0" text="indolin" /></sentence><sentence text=" Among them, the indolin oxidation and the omega-1 oxidation were dominant and were mainly catalyzed by CYP3A4 and CYP2D6, respectively"><entity charOffset="17-24" id="DDI-PubMed.18056254.s5.e0" text="indolin" /></sentence><sentence text=" The intrinsic clearance (CL(int)) values for these pathways in human hepatic microsomes were 0" /><sentence text="63 and 0" /><sentence text="76 microl/min/mg-protein, respectively" /><sentence text=" On the other hand, the metabolic reaction for R-125528 was restricted" /><sentence text=" It was demonstrated that omega-1 oxidation was the only pathway that could eliminate R-125528 from the systemic circulation" /><sentence text=" To our surprise, only CYP2D6-expressing microsomes could catalyze the reaction, and omega-1 oxidation was strongly correlated with the CYP2D6 marker reaction, dextromethorphan O-demethylation (r(2) = 0"><entity charOffset="160-176" id="DDI-PubMed.18056254.s11.e0" text="dextromethorphan" /></sentence><sentence text="90), in human hepatic microsomes" /><sentence text=" Although R-125528 is an atypical substrate for CYP2D6 because of its acidity, the K(m) value was 1" /><sentence text="8 microM for the reaction in human hepatic microsomes and the CL(int) value was as high as 75" /><sentence text="0 microl/min/mg-protein" /><sentence text=" These results suggested that the systemic clearance of R-125528 was highly dependent on CYP2D6 activity and that several studies with CYP2D6 including drug-drug interaction and polymorphism sensitivity should be performed during development from the viewpoint of metabolite safety assessment" /><sentence text=" The finding that R-125528, an acidic compound devoid of basic nitrogen, was a good substrate for CYP2D6 raised a question about previously reported CYP2D6 models based on a critical electrostatic interaction with Asp(301) and/or Glu(216)"><entity charOffset="63-71" id="DDI-PubMed.18056254.s17.e0" text="nitrogen" /></sentence><sentence text="" /></document>